New-generation efflux pump inhibitors

Area of Science:

• Pharmacology
• Drug Delivery
• Medicinal Chemistry

Background:

• Efflux pumps play a significant role in multidrug resistance, impacting cancer therapy efficacy.
• Developing novel efflux pump inhibitors is critical for improving drug delivery across biological barriers.
• The intestine and blood-brain barrier are key sites where efflux pump inhibition shows therapeutic promise.

Purpose of the Study:

• To review the current landscape of efflux pump inhibitors.
• To highlight the potential of both small molecule and polymeric inhibitors in drug delivery.
• To discuss advancements in targeting efflux pumps in the intestine and blood-brain barrier.

Main Methods:

• Review of existing literature on efflux pump inhibitors.
• Discussion of small molecule inhibitors, including third-generation compounds evaluated in clinical trials.
• Exploration of polymeric and polymer-based inhibitors, such as PEG, poloxamers, and thiomers.

Main Results:

• Several third-generation small molecule efflux pump inhibitors have advanced to clinical trials.
• Polymeric and polymer-based inhibitors represent a promising alternative or complementary approach.
• Targeting efflux pumps in the intestine and blood-brain barrier offers significant potential for enhanced drug delivery.

Conclusions:

• Efflux pump inhibitors are vital for overcoming drug resistance and improving therapeutic outcomes.
• Both small molecule and polymeric inhibitors warrant further investigation for their therapeutic applications.
• Targeted inhibition of efflux pumps holds promise for advanced drug delivery strategies.